PB
PB8.F Phibro Animal Health Corporation
- Market cap
- EUR 1.27B
- P/E
- 14.5x
- P/B
- 3.34x
- ROE
- 28.3%
- Dividend yield
- 1.40%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is PB8.F undervalued?
Graham numberPB8.F trades 47.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Phibro Animal Health Corporation fundamental analysis
No fundamental analysis for Phibro Animal Health Corporation yet.
Phibro Animal Health Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers anima…
Full company profilePhibro Animal Health Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Phibro Animal Health Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 764M | 820M | 828M | 800M | 833M | 942M | 978M | 1.02B | 1.30B | 1.52B | 1.55B |
| Gross Profit | 248M | 267M | 265M | 257M | 271M | 285M | 298M | 313M | 400M | 513M | 514M |
| Operating Income | 97.9M | 98.9M | 83.2M | 69.2M | 74.9M | 79.0M | 71.8M | 53.3M | 110M | 194M | 199M |
| EBITDA | 123M | 129M | 113M | 102M | 111M | 117M | 106M | 69.1M | 147M | 233M | 256M |
| Net Income | 64.6M | 64.9M | 54.7M | 33.6M | 54.4M | 49.2M | 32.6M | 2.42M | 48.3M | 99.7M | 118M |
| EPS | 1.62 | 1.61 | 1.35 | 0.83 | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 | 2.46 | 2.91 |
| Balance Sheet | |||||||||||
| Total Assets | 623M | 672M | 727M | 784M | 841M | 932M | 971M | 982M | 1.36B | 1.50B | 1.51B |
| Total Liabilities | 472M | 487M | 511M | 596M | 603M | 669M | 689M | 726M | 1.08B | 1.12B | 1.10B |
| Shareholders' Equity | 151M | 185M | 216M | 188M | 239M | 262M | 283M | 257M | 286M | 385M | 418M |
| Cash & Short-term Investments | 56.1M | 29.2M | 57.6M | 36.3M | 50.2M | 74.2M | 41.3M | 70.6M | 68.0M | 61.4M | 75.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 98.4M | 70.0M | 47.2M | 59.3M | 48.3M | 31.6M | 13.3M | 87.6M | 80.1M | 69.0M | 104M |
| Capital Expenditure | 20.9M | 18.5M | 29.9M | 34.0M | 29.3M | 37.0M | 51.8M | 41.2M | 38.3M | 59.1M | 75.1M |
| Free Cash Flow | 77.5M | 51.5M | 17.3M | 25.3M | 19.0M | -5.40M | -38.5M | 46.4M | 41.8M | 9.87M | 29.2M |
| Ratios | |||||||||||
| ROE | 42.7% | 35.1% | 25.3% | 17.8% | 22.8% | 18.7% | 11.5% | 0.9% | 16.9% | 25.9% | 28.3% |
| ROA | 10.4% | 9.7% | 7.5% | 4.3% | 6.5% | 5.3% | 3.4% | 0.2% | 3.5% | 6.6% | 7.8% |
| Net Profit Margin | 8.5% | 7.9% | 6.6% | 4.2% | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% | 6.6% | 7.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Phibro Animal Health Corporation dividends
- Dividend yield
- 1.40%
- Forward dividend
- 0.43 EUR
- Payout ratio
- 19.5%
- Ex-dividend date
- Nov 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 19.5M | 0.48 | 19.5% |
| 2025 | USD 19.4M | 0.48 | 40.3% |
| 2024 | USD 19.4M | 0.48 | 804.7% |
| 2023 | USD 19.4M | 0.48 | 59.6% |
| 2022 | USD 19.4M | 0.48 | 39.5% |
| 2021 | USD 19.4M | 0.48 | 35.7% |
| 2020 | USD 19.4M | 0.48 | 57.9% |
| 2019 | USD 18.6M | 0.46 | 34.0% |
| 2018 | USD 16.1M | 0.40 | 24.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Phibro Animal Health Corporation
- Insiders 0.88%
- Institutions 99.12%
- Public & others 0.00%
- Shares outstanding 21.1M
- Free float 20.9M
Phibro Animal Health Corporation company profile
- Company name
- Phibro Animal Health Corporation
- Ticker
- PB8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,605
- Fiscal year end
- June
- Address
- Glenpointe Centre East, Teaneck, NJ, United States, 07666-6712
- Phone
- 201 329 7300
- Website
- pahc.com
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
Phibro Animal Health Corporation management
10- Mr. Jack Clifford BendheimExecutive Chairman · born 1947
- Mr. Daniel M. Bendheim J.D.CEO, President & Director · born 1972
- Mr. Glenn C. DavidChief Financial Officer · born 1972
- Mr. Larry L. MillerChief Operating Officer · born 1964
- Ms. Judith A. WeinsteinSenior VP, General Counsel & Corporate Secretary · born 1969
- Mr. Jonathan BendheimExecutive VP of Talent, Technology and Business Development & Director · born 1976
- Ms. Lisa Ann EscuderoSenior Vice President of Human Resources · born 1962
- Mr. Ramon FuenmayorPresident South America Region
- Mr. Samson LiPresident of Asia Pacific Region · born 1972
- Mr. Todd ArmstrongPresident of North American Region